OR WAIT null SECS
- Advertise
- About Us
- Editorial Board
- Contact Us
- Job Board
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Infection Control Today. All rights reserved.
Reduction in HPV in Young Women in England Achieved After National Immunization Program
Each year around 2,000 to 2,500 women are diagnosed with cervical cancer in England, the most common cancer in women under 35. Infection with high-risk human papillomavirus (HR HPV) types 16 and 18 is responsible for around 70 percent to 80 percent of cervical cancers. A study conducted by Public Health England and presented at the Society for General Microbiology's Annual Conference shows a reduction in these two HR HPV types – which are included in the HPV vaccines used – in sexually active young women in England.
Between 2010 and 2012, more than 4,000 samples were collected from young women receiving a chlamydia screen as part of the National Chlamydia Screening Program in England. Prior to the HPV immunization program introduction, a survey showed around 1 in 5 sexually active women aged 16 to 18 were infected with at least one of the two HPV types included in vaccines. A similar survey conducted following the introduction of the program showed the prevalence had dropped to 1 in 15 young women.
Post-immunization prevalence of HPV types 16 and 18 infection was lowest among women aged 16 to 18 year old, the age group with the highest vaccination coverage. Prior to the immunization program, this age group was shown to have the highest prevalence of infection.
David Mesher, of Public Health England, presenting the work at the conference, says, "This study provides an early indication that the national HPV immunization program is successfully reducing vaccine-type HPV infections in sexually active young women in England, and also suggests herd-immunity may be benefiting non-vaccinated young women and men. The data provide reassurance that the high efficacy against HPV infection in women reported in clinical trials can be effectively realised in practice, and in a program achieving high coverage amongst young females. These data adds to our confidence that the HPV immunization program will achieve its aim of reducing cervical cancer."
Source: Public Health England